Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FLT3 2322 SORAFENIB CHEMBL1336 antagonist, inhibitor TALC, TdgClinicalTrial, OncoKB, CKB, GuideToPharmacologyInteractions, NCI, CIViC, TEND, DrugBank, DoCM 17229632, 17205056, 18230792, 15466206, 22368270, 22504184, 23969938, 23392356, 25848357, 23613521, 20733134, 23321257, 23714533, 15256420, 22504183, 15374878, 16857985, 23783394, 23261068, 19657110, 25157968, 11290608, 23430109, 14604974, 24046014, 17606455, 17047150, 22504185, 17889720
FLT3 2322 CRENOLANIB CHEMBL2105728 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions, CGI, DoCM, MyCancerGenomeClinicalTrial 24623852, 24619500, 22504184, 23430109, 23878140
FLT3 2322 DORSOMORPHIN CHEMBL478629 inhibitor GuideToPharmacologyInteractions
FLT3 2322 ENMD-2076 CHEMBL482968 inhibitor TALC, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions 27406088
FLT3 2322 CHEMBL406375 CHEMBL406375 inhibitor GuideToPharmacologyInteractions
FLT3 2322 KW-2449 CHEMBL1908397 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT3 2322 MIDOSTAURIN CHEMBL608533 inhibitor GuideToPharmacologyInteractions, CIViC, CKB, FDA, MyCancerGenome, TdgClinicalTrial, MyCancerGenomeClinicalTrial, CGI, DoCM, ChemblInteractions 20733134, 28546144, 15345593, 22627678, 12124173, 18068628, 28644114, 25530214, 23392356, 24619500, 22504184, 23430109, 23878140, 23321257, 23714533, 15256420, 22504183, 15374878, 22368270, 16857985, 23783394, 23261068, 19657110, 25157968, 11290608, 14604974, 24046014, 17606455, 17047150, 22504185, 17889720
FLT3 2322 QUIZARTINIB CHEMBL576982 inhibitor MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CGI, CIViC, DoCM 23392356, 27099147, 26920889, 24002496, 22504184, 23878140, 23430109, 24619500, 20733134, 23321257, 23714533, 15256420, 22504183, 15374878, 22368270, 16857985, 23783394, 23261068, 19657110, 25157968, 11290608, 14604974, 24046014, 17606455, 17047150, 22504185, 17889720
FLT3 2322 SUNITINIB CHEMBL535 inhibitor GuideToPharmacologyInteractions, DrugBank, TEND, TdgClinicalTrial, TALC, MyCancerGenomeClinicalTrial, MyCancerGenome, CIViC, CKB 15180525, 14753710, 11752352, 15304385, 12531805, 14654525, 19667267, 27181063, 23392356, 25818407
FLT3 2322 TANDUTINIB CHEMBL124660 inhibitor GuideToPharmacologyInteractions, DrugBank, TdgClinicalTrial, MyCancerGenome, CIViC, CKB, ChemblInteractions 15256420, 12124172, 27099147
FLT3 2322 AMUVATINIB CHEMBL2103851 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions, DrugBank
FLT3 2322 CLOFARABINE CHEMBL1750 inhibitor MyCancerGenomeClinicalTrial
FLT3 2322 CHEMBL2062155 CHEMBL2062155 CIViC 15626738, 19318574
FLT3 2322 NILOTINIB CHEMBL255863 CIViC 28720666
FLT3 2322 E-6201 CHEMBL1097999 CKB 26822154
FLT3 2322 CYTARABINE CHEMBL803 CKB 22627678, 25818407, 28644114, 27626069
FLT3 2322 CHEMBL2169919 CHEMBL2169919 CKB 27535106
FLT3 2322 ENMD-981693 CHEMBL52885 inhibitor ChemblInteractions
FLT3 2322 SU-14813 CHEMBL3545160 inhibitor ChemblInteractions
FLT3 2322 AT-9283 CHEMBL495727 inhibitor ChemblInteractions
FLT3 2322 Famitinib CHEMBL3545026 inhibitor ChemblInteractions
FLT3 2322 AKN-028 CHEMBL3545281 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT3 2322 AST-487 CHEMBL574738 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT3 2322 BMS-690514 CHEMBL3545396 inhibitor GuideToPharmacologyInteractions
FLT3 2322 CEDIRANIB CHEMBL491473 inhibitor GuideToPharmacologyInteractions
FLT3 2322 JNJ-40346527 CHEMBL3545319 inhibitor GuideToPharmacologyInteractions
FLT3 2322 TG-02 CHEMBL1944698 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions 21860433
FLT3 2322 NINTEDANIB CHEMBL502835 Inhibitor DrugBank 18559524
FLT3 2322 SEMAXANIB CHEMBL276711 NCI 15158089
FLT3 2322 BORTEZOMIB CHEMBL325041 inhibitor MyCancerGenomeClinicalTrial
FLT3 2322 RG-1530 CHEMBL1980391 inhibitor ChemblInteractions
FLT3 2322 FEDRATINIB CHEMBL1287853 inhibitor ChemblInteractions
FLT3 2322 SUNITINIB MALATE CHEMBL1567 inhibitor ChemblInteractions
FLT3 2322 CEP-2563 CHEMBL3545332 inhibitor ChemblInteractions
FLT3 2322 C-1311 (CHEMBL3545337) CHEMBL3545337 inhibitor ChemblInteractions
FLT3 2322 FORETINIB CHEMBL1230609 inhibitor ChemblInteractions
FLT3 2322 CERITINIB CHEMBL2403108 inhibitor GuideToPharmacologyInteractions
FLT3 2322 CHEMBL377193 CHEMBL377193 inhibitor GuideToPharmacologyInteractions
FLT3 2322 LESTAURTINIB CHEMBL603469 inhibitor GuideToPharmacologyInteractions, TdgClinicalTrial, MyCancerGenome, CGI, DoCM, ChemblInteractions 20733134, 22504184, 23321257, 23714533, 15256420, 22504183, 15374878, 22368270, 16857985, 23783394, 23261068, 19657110, 25157968, 11290608, 23430109, 14604974, 24046014, 17606455, 17047150, 22504185, 17889720
FLT3 2322 MK-2461 CHEMBL1822792 inhibitor GuideToPharmacologyInteractions
FLT3 2322 NMS-1286937 CHEMBL1094408 inhibitor GuideToPharmacologyInteractions
FLT3 2322 PONATINIB CHEMBL1171837 inhibitor MyCancerGenome, CKB, CGI, CIViC, DrugBank, DoCM 23430109, 21482694, 23691988, 24619500, 22504184, 20733134, 23321257, 23714533, 15256420, 22504183, 15374878, 22368270, 16857985, 23783394, 23261068, 19657110, 25157968, 11290608, 14604974, 24046014, 17606455, 17047150, 22504185, 17889720
FLT3 2322 DAUNORUBICIN CHEMBL178 CKB, NCI, CIViC 15626738, 22627678, 25818407, 28644114
FLT3 2322 CABOZANTINIB CHEMBL2105717 inhibitor MyCancerGenome, CKB 21926191
FLT3 2322 AZACITIDINE CHEMBL1489 inhibitor CKB, MyCancerGenomeClinicalTrial 25530214, 23613521
FLT3 2322 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
FLT3 2322 TRETINOIN CHEMBL38 CKB, CIViC 19965647, 24981688, 27626069
FLT3 2322 BRIGATINIB CHEMBL3545311 CKB 27780853
FLT3 2322 ALTIRATINIB CHEMBL3545365 CKB 26285778
FLT3 2322 4SC-203 CHEMBL3545358 inhibitor ChemblInteractions
FLT3 2322 CT-1578 CHEMBL3544962 inhibitor ChemblInteractions
FLT3 2322 CM-082 CHEMBL3545427 inhibitor ChemblInteractions
FLT3 2322 DOVITINIB CHEMBL522892 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT3 2322 CHEMBL2218935 CHEMBL2218935 inhibitor GuideToPharmacologyInteractions
FLT3 2322 LINIFANIB CHEMBL223360 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
FLT3 2322 PF-562271 CHEMBL1084546 inhibitor GuideToPharmacologyInteractions
FLT3 2322 RGB-286638 CHEMBL3545083 inhibitor GuideToPharmacologyInteractions
FLT3 2322 TAK-659 CHEMBL3544931 inhibitor GuideToPharmacologyInteractions
FLT3 2322 PROPAFENONE CHEMBL631 GuideToPharmacologyInteractions
FLT3 2322 XL-999 CHEMBL3545285 inhibitor TALC, TdgClinicalTrial, ChemblInteractions, DrugBank
FLT3 2322 IMATINIB CHEMBL941 CKB 15345593
FLT3 2322 VS-5584 CHEMBL1079593 CKB 23270925
FLT3 2322 SU-014813 CHEMBL1721885 inhibitor ChemblInteractions
FLT3 2322 PLX-3397 CHEMBL3545158 inhibitor MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CancerCommons 25847190
FLT3 2322 GELDANAMYCIN CHEMBL278315 NCI 15150124, 15514006
FLT3 2322 REBASTINIB CHEMBL1738757 CKB 27927766
FLT3 2322 METHOTREXATE CHEMBL34259 CKB 27626069
FLT3 2322 ARSENIC TRIOXIDE CHEMBL1200978 CKB 27626069
FLT3 2322 PACRITINIB CHEMBL2035187 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions 22829080
FLT3 2322 HERBIMYCIN CHEMBL479533 NCI 12145695
FLT3 2322 CHEMBL71191 CHEMBL71191 CIViC 12357354, 17330097
FLT3 2322 AS-602868 CHEMBL129857 inhibitor ChemblInteractions, CIViC 17330097
FLT3 2322 CHEMBL210833 CHEMBL210833 CKB 27099147
FLT3 2322 GILTERITINIB CHEMBL3301622 inhibitor CKB, ChemblInteractions 28645776
FLT3 2322 SGI-1776 CHEMBL1952329 inhibitor CKB, GuideToPharmacologyInteractions 27099147
FLT3 2322 PALBOCICLIB CHEMBL189963 CKB 27099147
FLT3 2322 CHEMBL35482 CHEMBL35482 CKB 18068628

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FLT3 rs1933437 AA sunitinib efficacy no The genotype was not associated with progression free survival, or overall survival either. Clinical benefit was defined as either partial response or stable disease. Please note, alleles have been complemented to the + chromosomal strand. Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG. 26244574 1446706623
FLT3 rs1933437 G imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Please note that alleles have been complemented to the positive strand. Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A. 30713339 1450933593